for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Takeda Pharmaceutical Co Ltd

4502.T

Latest Trade

3,798.00JPY

Change

41.00(+1.09%)

Volume

7,566,900

Today's Range

3,744.00

 - 

3,814.00

52 Week Range

3,401.00

 - 

4,943.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
3,757.00
Open
3,759.00
Volume
7,566,900
3M AVG Volume
96.46
Today's High
3,814.00
Today's Low
3,744.00
52 Week High
4,943.00
52 Week Low
3,401.00
Shares Out (MIL)
1,576.36
Market Cap (MIL)
5,987,004.00
Forward P/E
-21.41
Dividend (Yield %)
4.74

Next Event

Dividend For 4502.T - 90.0000 JPY

Latest Developments

More

Takeda Issues U.S. Recall Of NATPARA For Injection Due To The Potential For Rubber Particulate

Kamada Says Will Now Continue To Produce Glassia For Takeda Through 2021

Kamada Reports Discussions With Takeda Regarding A Potential Extension Of The Period For The Transition Of Glassia Manufacturing To Takeda

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Takeda Pharmaceutical Co Ltd

Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.

Industry

Major Drugs

Contact Info

4F, 2-1-1, Nihombashihon-cho

+81.3.32782111

https://www.takeda.com/

Executive Leadership

Masahiro Sakane

Independent Chairman of the Executive Board

Christophe Weber

President, Chief Executive Officer, Representative Director

Constantine Saroukos

Chief Financial Officer, Director

Masato Iwasaki

President of Japan Pharma Business Unit, President of Subsidiary, Director

Andrew S. Plump

President of Research & Development, Director

Key Stats

1.92 mean rating - 12 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2017

1.7K

2018

1.8K

2019

2.1K

2020(E)

3.3K
EPS (JPY)

2017

147.150

2018

239.350

2019

113.500

2020(E)

-179.920
Price To Earnings (TTM)
64.25
Price To Sales (TTM)
2.40
Price To Book (MRQ)
1.22
Price To Cash Flow (TTM)
14.24
Total Debt To Equity (MRQ)
116.06
LT Debt To Equity (MRQ)
105.37
Return on Investment (TTM)
0.14
Return on Equity (TTM)
0.12

Latest News

Fresenius Medical Care appoints Takeda executive Helen Giza as CFO

German dialysis specialist Fresenius Medical Care <FMEG.DE> has hired Helen Giza from Japan's Takeda Pharmaceutical <4502.T> as its new finance chief, replacing Mike Brosnan.

Takeda kicks off sale of Western European drugs: sources

Japan's Takeda Pharmaceutical Co <4502.T> has reached out to prospective bidders for a portfolio of drugs for sale in western Europe as it seeks to trim its debt following the $59 billion purchase of Shire, sources close to the matter told Reuters.

Olympics: Japan's Yamashita appointed chief as Takeda resigns in graft probe

The Japanese Olympic Committee (JOC) picked former Olympic judo champion Yasuhiro Yamashita as its new chief after the resignation of Tsunekazu Takeda, who is being investigated for suspected corruption related to the Tokyo 2020 bid.

Takeda scraps late-stage amyloidosis study

Takeda Pharmaceutical Co Ltd said on Wednesday it would discontinue a late-stage study testing its experimental treatment for amyloidosis, as it did not meet the first of two main goals.

Japan's Takeda expects binding offers for Latam business by end of May: sources

Japan's Takeda Pharmaceutical Co expects to receive binding offers for its Latin American business by the end of May, three sources with knowledge of the matter said.

Japan's Takeda forecasts surprise annual loss on Shire-related costs

Takeda Pharmaceutical Co forecast an unexpected operating loss for the current year due to costs associated with the $59 billion purchase of Shire Plc, providing the first set of financial results of the combined firm.

Japan's Takeda expects annual loss on Shire deal

Takeda Pharmaceutical Co forecast on Tuesday it would have an operating loss in the current financial year, as it books costs associated with the multibillion-dollar Shire deal.

Novartis buys dry eye drug from Takeda for up to $5.3 billion

Novartis is buying dry-eye drug Xiidra from Takeda Pharmaceutical Co for up to $5.3 billion as the Swiss drugmaker refreshes its ophthalmic medicines portfolio with a potential blockbuster.

Novartis buys Takeda's dry eye drug for $3.4 bln

Swiss drugmaker Novartis AG said on Wednesday it agreed to acquire Takeda Pharmaceutical Company Ltd's dry eye drug Xiidra for an upfront payment of $3.4 billion to expand its portfolio of eye care medicines.

Japan's Takeda invites Brazilian pharmaceutical firms to bid for Latam business: sources

Japan's Takeda Pharmaceutical Co Ltd has invited Brazilian pharmaceutical companies and financial investors to bid for its business in Latin America, three people with knowledge of the matter said.

Japan's Takeda invites Brazilian pharmaceutical firms to bid for Latam business- sources

Japan's Takeda Pharmaceutical Co Ltd has invited Brazilian pharmaceutical companies and financial investors to bid for its business in Latin America, three people with knowledge of the matter said.

Olympics: IOC wants new Japan member as soon as possible - Bach

The International Olympic Committee (IOC) is looking to appoint a new member for Japan soon following the departure of Japan Olympic Committee (JOC) chief Tsunekazu Takeda from the global ruling body, IOC President Thomas Bach said on Wednesday.

Olympics: Japan's Takeda no longer an IOC member - IOC

Japanese Olympic Committee (JOC) chief Tsunekazu Takeda, who is under investigation in France for suspected corruption and will step down from his role in June, is no longer an International Olympic Committee member, the IOC said on Tuesday.

Olympics: Japan chief Takeda to quit as corruption probe continues

Japanese Olympic Committee (JOC) chief Tsunekazu Takeda, who is under investigation for suspected corruption, said on Tuesday he will step down when his term ends in June and resign from the International Olympic Committee.

U.S. jury orders Takeda to pay Bayer $155 million over hemophilia drug

A U.S. jury has ordered Takeda Pharmaceutical Co's Baxalta unit to pay Bayer AG $155.19 million for infringing a patent related to a Baxalta hemophilia treatment, court records made public on Tuesday show.

U.S. jury orders Takeda to pay Bayer $155 million over hemophilia drug

A U.S. jury has ordered Takeda Pharmaceutical Co's Baxalta unit to pay Bayer AG $155.19 million for infringing a patent related to a Baxalta hemophilia treatment, court records made public on Tuesday show.

Olympics: Tokyo 2020 head says no need for Takeda to resign

Japanese Olympic Committee President Tsunekazu Takeda, being probed for suspected corruption, does not need to step down from his role with the Tokyo 2020 organising committee because current "reports" do not justify action, the head of Tokyo 2020 said.

UPDATE 1-Takeda's Q3 profit rises 28 pct on strong sales of main drugs

* Boosted by strong sales of bowel disease, multiple myeloma drugs (Adds sales details, divesting plans)

Japan's Takeda posts 28 pct rise in Q3 operating profit

Takeda Pharmaceutical Co Ltd on Friday posted a 27.9 percent rise in third-quarter operating profit, supported by strong sales of its drugs for bowel disease and multiple myeloma.

Undeterred by Sanofi's stumble, Takeda takes similar path with dengue shot

A new vaccine for the dengue virus is taking a potentially risky road to prevent the mosquito-borne disease that infects nearly 400 million people each year.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up